Choriogonadotropin alfa - Merck Serono

Drug Profile

Choriogonadotropin alfa - Merck Serono

Alternative Names: Chorionic gonadotropin - Merck-Serono; Ovidrel; Ovitrelle; rhCG

Latest Information Update: 05 Jul 2011

Price : $50

At a glance

  • Originator Merck Serono
  • Class Infertility therapies; Peptide hormones; Pituitary gonadotropins; Placental hormones; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Female infertility
  • Discontinued Breast cancer; Hypogonadism; Male infertility

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top